ASH 2021 Conference Coverage on VuMedi

 

ASH 2021 Conference Coverage on VuMedi
J

ASH 2021 Update on BOVen in CLL: Early MRD Kinetics Define a High-Risk Patient Cohort With Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence

By ASH 2021 Conference Coverage on VuMedi FEATURING Jake Soumerai
By ASH 2021 Conference Coverage on VuMedi FEATURING Jake Soumerai
27 views
December 16, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
Leukemia
06:56
ASH 2021 Conference Coverage on VuMedi

Acalabrutinib vs. Rituximab + Idelalisib/Bendamustine in R/R CLL: 3-…

Feat. P. Ghia
08:45
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updated Results From the Phase 3 QUAZAR AML-001 Trial: Long…

Feat. A. Wei
10:00
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Asciminib vs. Investigator-Selected TKI in Newly…

Feat. J. Cortés
12:00
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights on ALLG Phase 2 INTERVENE Study: Investigating N…

Feat. C. Chua
08:50
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Results From the SEQUOIA Study: Zanubrutinib vs. Bendamusti…

Feat. C. Tam
07:00
ASH 2021 Conference Coverage on VuMedi

ASH 2021 on a Study of Venetoclax and Low Dose Ara-C (VALDAC) to Tar…

Feat. T. Ing Soo
12:07
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Long Term Follow-Up and Combined Phase 2 Results of Eprenet…

Feat. D. Sallman
11:06
ASH 2021 Conference Coverage on VuMedi

ASH 2021 MRD Assessment in CLL

Feat. P. Ghia
05:49
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Safety & Efficacy of Menin Inhibition in …

Feat. E. Stein
08:38
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Clinical Predictors of Outcomes in Adult Acute Leukemias an…

Feat. P. Desai
09:55
ASH 2021 Conference Coverage on VuMedi

ASH 2021: Comparing Outcomes Between CPX-351 and HMA+Ven As 1L Thera…

Feat. P. Desai
12:29
ASH 2021 Conference Coverage on VuMedi

ASH 2021 on Older Patients With AML: So I Am in Remission - Now What?

Feat. P. Desai
05:46
ASH 2021 Conference Coverage on VuMedi

ASH 2021: Outcomes of Patients Treated With CPX-351 as 1L Therapy fo…

Feat. A. Jain
21:44
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Efficacy and AE Management of BTKi in CLL/SLL

Feat. J. Rhodes
11:34
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Novel Advances in AML Therapy

Feat. E. Wang
17:05
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Therapy of p53 Mutant Hematologic Malignancies

Feat. M. Davids
07:41
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on BOVen in CLL: Early MRD Kinetics Define a High-Ri…

Feat. J. Soumerai
24:40
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on MRD in ALL: Standard of Care & Areas for Furt…

Feat. L. Muffly
10:28
ASH 2021 Conference Coverage on VuMedi

ASH 2021 MRD Directed Therapy: A New Frontier in AML

Feat. A. Wei